{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:32:18Z","timestamp":1772811138550,"version":"3.50.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["81903948, 81873330"],"award-info":[{"award-number":["81903948, 81873330"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["81903948, 81873330"],"award-info":[{"award-number":["81903948, 81873330"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ovarian malignant mesoderm mixed tumor (OMMMT) is a rare clinical entity. To provide reference for the treatment and prognosis of OMMMT, we analyzed the clinical features, pathology and molecular biology characteristic of published cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The English and Chinese reported cases of OMMMT were selected from PubMed, Clinical Trials.gov and CNKI database from 2000 to December 15th, 2021 following the PRISMA guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 63 literatures including 199 OMMMT cases were included. The average age of patients at diagnosis was 56.46\u2009years, the highest incidence age was 60-65\u2009years, and 82% of them were menopausal women. Most patients were diagnosed in FIGO III stage (59.64%). The most common symptom of OMMMT was abdominal pain (60.5%). 61.6% of patients were accompanied by ascites, while ascites was not associated with metastatic tumor and local recurrence. The CA125 of 88.68% patients increased. The most common reported carcinomatous component and sarcomatous component were serous adenocarcinoma (44.96%) and chondrosarcoma (24.81%), respectively. Initial treatment included surgery (94.97%) and taxanes-based (55.10%) or platinum-based (85.71%) chemotherapy regimens. The median survival time of patients was 20\u2009months. Heterologous sarcoma component did not shorten life expectancy. The optimal ovarian tumor cell debulking surgery (OOTCDS), radiotherapy and chemotherapy could significantly prolong the median survival time of patients. Furthermore, platinum drugs could significantly prolong the survival time after comparing various chemotherapy schemes. Besides, the combination of platinum and taxanes was therapeutically superior to the combination of platinum and biological alkylating agents.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The OOTCDS and platinum-based chemotherapy regimen can improve the prognosis of OMMMT. Targeted therapy might become a new research direction in the future. Since the elderly patients are the majority, the toxicity of new drugs on the elderly patients is more noteworthy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-022-01037-6","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T14:02:48Z","timestamp":1663336968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review"],"prefix":"10.1186","volume":"15","author":[{"given":"Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"issue":"4","key":"1037_CR1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3322\/caac.20121","volume":"61","author":"R Siegel","year":"2011","unstructured":"Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212\u201336.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1037_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.4103\/0377-4929.125293","volume":"56","author":"S Menon","year":"2013","unstructured":"Menon S, Deodhar K, Rekhi B, Dhake R, Gupta S, Ghosh J, et al. Clinico-pathological spectrum of primary ovarian malignant mixed mullerian tumors (OMMMT) from a tertiary cancer institute: a series of 27 cases. Indian J Pathol Microbiol. 2013;56(4):365\u201371.","journal-title":"Indian J Pathol Microbiol"},{"issue":"3","key":"1037_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00428-007-0557-6","volume":"452","author":"A Schipf","year":"2008","unstructured":"Schipf A, Mayr D, Kirchner T, Diebold J. Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study. Virchows Arch. 2008;452(3):259\u201368.","journal-title":"Virchows Arch"},{"issue":"10","key":"1037_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/OGX.0b013e3181b8aff3","volume":"64","author":"LA Cantrell","year":"2009","unstructured":"Cantrell LA, Van Le L. Carcinosarcoma of the ovary a review. Obstet Gynecol Surv. 2009;64(10):673\u201380 quiz 97.","journal-title":"Obstet Gynecol Surv"},{"issue":"9 Suppl 3","key":"1037_CR5","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1097\/IGC.0000000000000228","volume":"24","author":"D Berton-Rigaud","year":"2014","unstructured":"Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S55\u201360.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"1037_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/COC.0b013e3182979b27","volume":"38","author":"C Pacaut","year":"2015","unstructured":"Pacaut C, Bourmaud A, Rivoirard R, Moriceau G, Guy JB, Collard O, et al. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy. Am J Clin Oncol. 2015;38(3):272\u20137.","journal-title":"Am J Clin Oncol"},{"issue":"1-2","key":"1037_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000328794","volume":"80","author":"V Loizzi","year":"2011","unstructured":"Loizzi V, Cormio G, Camporeale A, Falagario M, De Mitri P, Scardigno D, et al. Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature. Oncology. 2011;80(1-2):102\u20136.","journal-title":"Oncology."},{"issue":"1","key":"1037_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ygyno.2013.06.034","volume":"131","author":"EM George","year":"2013","unstructured":"George EM, Herzog TJ, Neugut AI, Lu YS, Burke WM, Lewin SN, et al. Carcinosarcoma of the ovary: natural history, patterns of treatment, and outcome. Gynecol Oncol. 2013;131(1):42\u20135.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1037_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13048-019-0507-3","volume":"12","author":"A Daimon","year":"2019","unstructured":"Daimon A, Fujiwara S, Tanaka Y, Tanaka T, Ohmichi M. A rare case of ovarian carcinosarcoma with squamous cell carcinoma. J Ovarian Res. 2019;12(1):32.","journal-title":"J Ovarian Res"},{"issue":"2","key":"1037_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","volume":"19","author":"DK Armstrong","year":"2021","unstructured":"Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian Cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19(2):191\u2013226.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1037_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejogrb.2021.05.005","volume":"262","author":"A Kanneganti","year":"2021","unstructured":"Kanneganti A, Bhadiraju P, Tong PSY. Extragonadal teratomas in women and adolescent girls: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2021;262:134\u201341.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"1037_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/diagnostics9040200","volume":"9","author":"A Nizam","year":"2019","unstructured":"Nizam A, Bustamante B, Shan W, Shih KK, Whyte JS, Sakaris A, et al. Overall Survival and adjuvant therapy in women with ovarian Carcinosarcoma: a single-institution experience. Diagnostics (Basel). 2019;9(4):200.","journal-title":"Diagnostics (Basel)"},{"issue":"10","key":"1037_CR13","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1002\/cncr.20256","volume":"100","author":"E Brown","year":"2004","unstructured":"Brown E, Stewart M, Rye T, Al-Nafussi A, Williams AR, Bradburn M, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer. 2004;100(10):2148\u201353.","journal-title":"Cancer."},{"issue":"2","key":"1037_CR14","first-page":"173","volume":"30","author":"JF Silverman","year":"1986","unstructured":"Silverman JF, Gardner J, Larkin EW, Finley JL, Norris HT. Ascitic fluid cytology in a case of metastatic malignant mixed mesodermal tumor of the ovary. Acta Cytol. 1986;30(2):173\u20136.","journal-title":"Acta Cytol"},{"issue":"11","key":"1037_CR15","first-page":"2179","volume":"38","author":"Z Pan","year":"2021","unstructured":"Pan Z, Li C, Li L. Clinical analysis of 16 cases of primary carcinosarcomas in ovarys. J Guangxi Med Univ. 2021;38(11):2179\u201383.","journal-title":"J Guangxi Med Univ"},{"key":"1037_CR16","first-page":"11645156","volume":"11","author":"Y Cui","year":"2021","unstructured":"Cui Y, Yao J, Wang S, Zhao J, Dong J, Liao L. The clinical and pathological characteristics of malignant Struma Ovarii: an analysis of 144 published patients. Front Oncol. 2021;11:11645156.","journal-title":"Front Oncol"},{"issue":"5","key":"1037_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s10552-005-0615-9","volume":"17","author":"R Roychoudhuri","year":"2006","unstructured":"Roychoudhuri R, Putcha V, M\u00f8ller H. Cancer and laterality: a study of the five major paired organs (UK). Cancer Causes Control. 2006;17(5):655\u201362.","journal-title":"Cancer Causes Control"},{"issue":"9","key":"1037_CR18","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1738::AID-CNCR21>3.0.CO;2-4","volume":"82","author":"AK Sood","year":"1998","unstructured":"Sood AK, Sorosky JI, Gelder MS, Buller RE, Anderson B, Wilkinson EJ, et al. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Cancer. 1998;82(9):1731\u20137.","journal-title":"Cancer."},{"issue":"11","key":"1037_CR19","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2002.20.11.2758","volume":"20","author":"DL Wickerham","year":"2002","unstructured":"Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol. 2002;20(11):2758\u201360.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1037_CR20","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/IGC.0b013e3181a83fbf","volume":"19","author":"O Lavie","year":"2009","unstructured":"Lavie O, Longacre T, Segev Y, Husain A. Ovarian carcinosarcomas associated with prolonged use of tamoxifen: case reports. Int J Gynecol Cancer. 2009;19(9):1521\u20133.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"1037_CR21","first-page":"256","volume":"19","author":"GM Makris","year":"2015","unstructured":"Makris GM, Siristatidis C, Battista MJ, Chrelias C. Ovarian carcinosarcoma: a case report, diagnosis, treatment and literature review. Hippokratia. 2015;19(3):256\u20139.","journal-title":"Hippokratia."},{"issue":"5","key":"1037_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1046\/j.1365-2559.2000.01015.x","volume":"37","author":"K Ariyoshi","year":"2000","unstructured":"Ariyoshi K, Kawauchi S, Kaku T, Nakano H, Tsuneyoshi M. Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases. Histopathology. 2000;37(5):427\u201336.","journal-title":"Histopathology."},{"issue":"1","key":"1037_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ygyno.2004.09.051","volume":"96","author":"MP Zorzou","year":"2005","unstructured":"Zorzou MP, Markaki S, Rodolakis A, Kastritis E, Bozas G, Dimopoulos MA, et al. Clinicopathological features of ovarian carcinosarcomas: a single institution experience. Gynecol Oncol. 2005;96(1):136\u201342.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"1037_CR24","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/j.1525-1438.2007.00919.x","volume":"17","author":"R Athavale","year":"2007","unstructured":"Athavale R, Thomakos N, Godfrey K, Kew F, Cross P, de Barros LA, et al. The effect of epithelial and stromal tumor components on FIGO stages III and IV ovarian carcinosarcomas treated with primary surgery and chemotherapy. Int J Gynecol Cancer. 2007;17(5):1025\u201330.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"1037_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1600-0463.2008.00757.x","volume":"116","author":"V N\u00e4yh\u00e4","year":"2008","unstructured":"N\u00e4yh\u00e4 V, Stenb\u00e4ck F. Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas. APMIS. 2008;116(2):107\u201317.","journal-title":"APMIS"},{"key":"1037_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.critrevonc.2018.12.006","volume":"134","author":"S Boussios","year":"2019","unstructured":"Boussios S, Karathanasi A, Zakynthinakis-Kyriakou N, Tsiouris AK, Chatziantoniou AA, Kanellos FS, et al. Ovarian carcinosarcoma: current developments and future perspectives. Crit Rev Oncol Hematol. 2019;134:46\u201355.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1037_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ygyno.2013.07.097","volume":"131","author":"JA Rauh-Hain","year":"2013","unstructured":"Rauh-Hain JA, Diver EJ, Clemmer JT, Bradford LS, Clark RM, Growdon WB, et al. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol. 2013;131(1):46\u201351.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1037_CR28","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/ijerph19031106","volume":"19","author":"A Cheung","year":"2022","unstructured":"Cheung A, Shah S, Parker J, Soor P, Limbu A, Sheriff M, et al. Non-Epithelial Ovarian Cancers: How Much Do We Really Know? Int J Environ Res Public Health. 2022;19(3):1106.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"1037_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13048-020-00728-2","volume":"13","author":"Q Xu","year":"2020","unstructured":"Xu Q, Zhang X, Zou Y. Primitive ovarian carcinosarcoma: a clinical and radiological analysis of five cases. J Ovarian Res. 2020;13(1):129.","journal-title":"J Ovarian Res"},{"issue":"2","key":"1037_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/uog.23733","volume":"59","author":"F Ciccarone","year":"2022","unstructured":"Ciccarone F, Biscione A, Moro F, Fischerova D, Savelli L, Munaretto M, et al. Imaging in gynecological disease (23): clinical and ultrasound characteristics of ovarian carcinosarcoma. Ultrasound Obstet Gynecol. 2022;59(2):241\u20137.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"6","key":"1037_CR31","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/RLU.0b013e31820aa165","volume":"36","author":"YW Chen","year":"2011","unstructured":"Chen YW, Lin CY, Hou PN, Lee CS, Hou MF, Tsai EM. Whole-body FDG PET\/CT in diagnosis of internal mammary nodal metastasis of ovarian carcinosarcoma. Clin Nucl Med. 2011;36(6):460\u20131.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"1037_CR32","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3892\/or.2017.5818","volume":"38","author":"N Liu","year":"2017","unstructured":"Liu N, Peng SM, Zhan GX, Yu J, Wu WM, Gao H, et al. Human chorionic gonadotropin \u03b2 regulates epithelial-mesenchymal transition and metastasis in human ovarian cancer. Oncol Rep. 2017;38(3):1464\u201372.","journal-title":"Oncol Rep"},{"issue":"1","key":"1037_CR33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3892\/ol.2016.4630","volume":"12","author":"S Gao","year":"2016","unstructured":"Gao S, Fan C, Huang H, Zhu C, Su M, Zhang Y. Effects of HCG on human epithelial ovarian cancer vasculogenic mimicry formation in vivo. Oncol Lett. 2016;12(1):459\u201366.","journal-title":"Oncol Lett"},{"issue":"4","key":"1037_CR34","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00404-021-06017-7","volume":"304","author":"J Chen","year":"2021","unstructured":"Chen J, Wang J, Cao D, Yang J, Shen K, Huang H, et al. Alpha-fetoprotein (AFP)-producing epithelial ovarian carcinoma (EOC): a retrospective study of 27 cases. Arch Gynecol Obstet. 2021;304(4):1043\u201353.","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"1037_CR35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.5468\/ogs.20117","volume":"63","author":"A Ikeda","year":"2020","unstructured":"Ikeda A, Yamaguchi K, Yamakage H, Abiko K, Satoh-Asahara N, Takakura K, et al. Serum lactate dehydrogenase is a possible predictor of platinum resistance in ovarian cancer. Obstet Gynecol Sci. 2020;63(6):709\u201318.","journal-title":"Obstet Gynecol Sci"},{"issue":"3","key":"1037_CR36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/humupd\/dmac004","volume":"28","author":"RA Anderson","year":"2022","unstructured":"Anderson RA, Cameron D, Clatot F, Demeestere I, Lambertini M, Nelson SM, et al. Anti-M\u00fcllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Hum Reprod Update. 2022;28(3):417\u201334.","journal-title":"Hum Reprod Update"},{"issue":"1","key":"1037_CR37","first-page":"1","volume":"9","author":"A Shariftabrizi","year":"2015","unstructured":"Shariftabrizi A, Pellicciotta I, Abdullah A, Venditti CA, Samuelson R, Shahabi S. Presence of both Mesenchymal and carcinomatous features in an in-vitro model of ovarian Carcinosarcoma derived from Patients\u2019 Ascitic fluid. Int J Hematol Oncol Stem Cell Res. 2015;9(1):1\u20134.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"6","key":"1037_CR38","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/1066896915583995","volume":"23","author":"S Jaiman","year":"2015","unstructured":"Jaiman S, Pochiraju M, Gundabattula SR, Surampudi K, Narayana Rao DV, Kandikattu S. Malignant transformation of pelvic endometriosis: case series and review of the literature. Int J Surg Pathol. 2015;23(6):465\u201371.","journal-title":"Int J Surg Pathol"},{"issue":"5","key":"1037_CR39","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/humrep\/dei462","volume":"21","author":"A Melin","year":"2006","unstructured":"Melin A, Spar\u00e9n P, Persson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod. 2006;21(5):1237\u201342.","journal-title":"Hum Reprod"},{"issue":"2","key":"1037_CR40","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/00004347-200104000-00004","volume":"20","author":"RC Stern","year":"2001","unstructured":"Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, Robboy SJ. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol. 2001;20(2):133\u20139.","journal-title":"Int J Gynecol Pathol"},{"issue":"04","key":"1037_CR41","first-page":"317","volume":"26","author":"L Zhang","year":"2010","unstructured":"Zhang L, Liu C, Zhang T. Recurrent malignant mullerian mixed tumor of ovary complicated with liver cirrhosis: a case report. Chin J Pract Gynecol Obstet. 2010;26(04):317\u20138.","journal-title":"Chin J Pract Gynecol Obstet"},{"issue":"4","key":"1037_CR42","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PGP.0000000000000507","volume":"38","author":"M Tavallaee","year":"2019","unstructured":"Tavallaee M, Steiner DF, Zehnder JL, Folkins AK, Karam AK. Coexistence of BRAF V600E and TERT promoter mutations in low-grade serous carcinoma of ovary recurring as Carcinosarcoma in a lymph node: report of a case. Int J Gynecol Pathol. 2019;38(4):386\u201392.","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"1037_CR43","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/PGP.0000000000000290","volume":"36","author":"IW Carnevali","year":"2017","unstructured":"Carnevali IW, Cimetti L, Sahnane N, Libera L, Cavallero A, Formenti G, et al. Two cases of Carcinosarcomas of the ovary involved in hereditary Cancer syndromes. Int J Gynecol Pathol. 2017;36(1):64\u201370.","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"1037_CR44","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s12253-020-00829-9","volume":"26","author":"A Travaglino","year":"2020","unstructured":"Travaglino A, Raffone A, Gencarelli A, Mollo A, Guida M, Insabato L, et al. TCGA classification of endometrial Cancer: the place of Carcinosarcoma. Pathol Oncol Res. 2020;26(4):2067\u201373.","journal-title":"Pathol Oncol Res"},{"issue":"8","key":"1037_CR45","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/ijc.30591","volume":"140","author":"FH Tang","year":"2017","unstructured":"Tang FH, Hsieh TH, Hsu CY, Lin HY, Long CY, Cheng KH, et al. KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice. Int J Cancer. 2017;140(8):1860\u20139.","journal-title":"Int J Cancer"},{"issue":"5","key":"1037_CR46","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/ijms18051100","volume":"18","author":"SG Vitale","year":"2017","unstructured":"Vitale SG, Lagan\u00e0 AS, Capriglione S, Angioli R, La Rosa VL, Lopez S, et al. Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives. Int J Mol Sci. 2017;18(5):1100.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1037_CR47","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/jcp.2005.029876","volume":"59","author":"KA Voutilainen","year":"2006","unstructured":"Voutilainen KA, Anttila MA, Sillanp\u00e4\u00e4 SM, Ropponen KM, Saarikoski SV, Juhola MT, et al. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol. 2006;59(5):460\u20137.","journal-title":"J Clin Pathol"},{"issue":"1","key":"1037_CR48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1046\/j.1365-2559.1998.00341.x","volume":"32","author":"BR Davies","year":"1998","unstructured":"Davies BR, Worsley SD, Ponder BA. Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology. 1998;32(1):69\u201380.","journal-title":"Histopathology."},{"issue":"12","key":"1037_CR49","first-page":"7351","volume":"34","author":"H Hirano","year":"2014","unstructured":"Hirano H, Kizaki T, Ito T, Okimura A, Yamanegi K, Nakasho K. Expression of adhesion molecules and the proliferative activity of carcinosarcoma of the ovary. Anticancer Res. 2014;34(12):7351\u20136.","journal-title":"Anticancer Res"},{"issue":"5","key":"1037_CR50","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3816\/CBC.2008.n.047","volume":"8","author":"JW Park","year":"2008","unstructured":"Park JW, Neve RM, Szollosi J, Benz CC. Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer. 2008;8(5):392\u2013401.","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"1037_CR51","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jconrel.2010.04.009","volume":"146","author":"W Tai","year":"2010","unstructured":"Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146(3):264\u201375.","journal-title":"J Control Release"},{"issue":"36","key":"1037_CR52","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.1200\/JCO.2006.07.0250","volume":"24","author":"Z Gabos","year":"2006","unstructured":"Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006;24(36):5658\u201363.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1037_CR53","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","volume":"17","author":"MA Cobleigh","year":"1999","unstructured":"Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639\u201348.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1037_CR54","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/PGP.0b013e31823bb24d","volume":"31","author":"F Guzzo","year":"2012","unstructured":"Guzzo F, Bellone S, Buza N, Hui P, Carrara L, Varughese J, et al. HER2\/neu as a potential target for immunotherapy in gynecologic carcinosarcomas. Int J Gynecol Pathol. 2012;31(3):211\u201321.","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"1037_CR55","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ygyno.2004.07.041","volume":"95","author":"F Amant","year":"2004","unstructured":"Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L, Moerman P, et al. ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecol Oncol. 2004;95(3):583\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1037_CR56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ygyno.2004.09.050","volume":"96","author":"MR Raspollini","year":"2005","unstructured":"Raspollini MR, Susini T, Amunni G, Paglierani M, Taddei A, Marchionni M, et al. COX-2, c-KIT and HER-2\/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Gynecol Oncol. 2005;96(1):159\u201367.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1037_CR57","doi-asserted-by":"publisher","first-page":"350","DOI":"10.5468\/ogs.2017.60.4.350","volume":"60","author":"HJ Kim","year":"2017","unstructured":"Kim HJ, Lee HM, Kim MK, Lee YK, Lee IH, Lee KH, et al. Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma. Obstet Gynecol Sci. 2017;60(4):350\u20136.","journal-title":"Obstet Gynecol Sci"},{"issue":"2","key":"1037_CR58","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ygyno.2016.06.003","volume":"142","author":"JA Rauh-Hain","year":"2016","unstructured":"Rauh-Hain JA, Birrer M, Del Carmen MG. Carcinosarcoma of the ovary, fallopian tube, and peritoneum: prognostic factors and treatment modalities. Gynecol Oncol. 2016;142(2):248\u201354.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1037_CR59","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1525-1438.2007.01074.x","volume":"18","author":"M Ozguroglu","year":"2008","unstructured":"Ozguroglu M, Bilici A, Ilvan S, Turna H, Atalay B, Mandel N, et al. Determining predominating histologic component in malignant mixed m\u00fcllerian tumors: is it worth it? Int J Gynecol Cancer. 2008;18(4):809\u201312.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"1037_CR60","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ygyno.2005.07.119","volume":"100","author":"TL Rutledge","year":"2006","unstructured":"Rutledge TL, Gold MA, McMeekin DS, Huh WK, Powell MA, Lewin SN, et al. Carcinosarcoma of the ovary-a case series. Gynecol Oncol. 2006;100(1):128\u201332.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1037_CR61","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ygyno.2011.02.023","volume":"121","author":"JA Rauh-Hain","year":"2011","unstructured":"Rauh-Hain JA, Growdon WB, Rodriguez N, Goodman AK, Boruta DM 2nd, Schorge JO, et al. Carcinosarcoma of the ovary: a case-control study. Gynecol Oncol. 2011;121(3):477\u201381.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1037_CR62","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ygyno.2014.03.002","volume":"133","author":"DW Doo","year":"2014","unstructured":"Doo DW, Erickson BK, Arend RC, Conner MG, Huh WK, Leath CA 3rd. Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma. Gynecol Oncol. 2014;133(2):234\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1037_CR63","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12885-018-4082-6","volume":"18","author":"M Brackmann","year":"2018","unstructured":"Brackmann M, Stasenko M, Uppal S, Erba J, Reynolds RK, McLean K. Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature. BMC Cancer. 2018;18(1):172.","journal-title":"BMC Cancer"},{"issue":"04","key":"1037_CR64","first-page":"357","volume":"33","author":"J Li","year":"2017","unstructured":"Li J, Wu X. How to improve the curative effect on ovarian carcinosarcoma. Chin J Pract Gynecol Obstet. 2017;33(04):357\u201360.","journal-title":"Chin J Pract Gynecol Obstet"},{"issue":"11","key":"1037_CR65","first-page":"e389","volume":"7","author":"JM Blanco Suarez","year":"2015","unstructured":"Blanco Suarez JM, Amendola BE, Perez N, Amendola M, Wu X. The use of lattice radiation therapy (LRT) in the treatment of bulky tumors: a case report of a large metastatic mixed Mullerian ovarian tumor. Cureus. 2015;7(11):e389.","journal-title":"Cureus."},{"issue":"1","key":"1037_CR66","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ygyno.2010.01.013","volume":"117","author":"HS Nimeiri","year":"2010","unstructured":"Nimeiri HS, Oza AM, Morgan RJ, Huo D, Elit L, Knost JA, et al. A phase II study of sorafenib in advanced uterine carcinoma\/carcinosarcoma: a trial of the Chicago, PMH, and California phase II consortia. Gynecol Oncol. 2010;117(1):37\u201340.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1037_CR67","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1525-1438.2006.00760.x","volume":"17","author":"MS Mano","year":"2007","unstructured":"Mano MS, Rosa DD, Azambuja E, Ismael G, Braga S, D'Hondt V, et al. Current management of ovarian carcinosarcoma. Int J Gynecol Cancer. 2007;17(2):316\u201324.","journal-title":"Int J Gynecol Cancer"},{"issue":"13","key":"1037_CR68","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","volume":"19","author":"BJ Chen","year":"2013","unstructured":"Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462\u201373.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1037_CR69","doi-asserted-by":"publisher","first-page":"e0170879","DOI":"10.1371\/journal.pone.0170879","volume":"12","author":"J Zhu","year":"2017","unstructured":"Zhu J, Wen H, Ju X, Bi R, Zuo W, Wu X. Clinical significance of programmed death Ligand-1 and intra-Tumoral CD8+ T lymphocytes in ovarian Carcinosarcoma. PLoS One. 2017;12(1):e0170879.","journal-title":"PLoS One"},{"issue":"2","key":"1037_CR70","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.18632\/oncotarget.6429","volume":"7","author":"S Darb-Esfahani","year":"2016","unstructured":"Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2016;7(2):1486\u201399.","journal-title":"Oncotarget."},{"issue":"23","key":"1037_CR71","doi-asserted-by":"publisher","first-page":"6900","DOI":"10.1158\/0008-5472.CAN-13-1550","volume":"73","author":"J Duraiswamy","year":"2013","unstructured":"Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 2013;73(23):6900\u201312.","journal-title":"Cancer Res"},{"issue":"1","key":"1037_CR72","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10585-014-9688-8","volume":"32","author":"R Nicoletti","year":"2015","unstructured":"Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, et al. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clin Exp Metastasis. 2015;32(1):29\u201338.","journal-title":"Clin Exp Metastasis"},{"issue":"19","key":"1037_CR73","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.1158\/1078-0432.CCR-16-2862","volume":"23","author":"G Menderes","year":"2017","unstructured":"Menderes G, Bonazzoli E, Bellone S, Black J, Predolini F, Pettinella F, et al. SYD985, a novel Duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian Carcinosarcoma with HER2\/Neu expression. Clin Cancer Res. 2017;23(19):5836\u201345.","journal-title":"Clin Cancer Res"},{"key":"1037_CR74","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13046-015-0241-7","volume":"34","author":"F Ferrari","year":"2015","unstructured":"Ferrari F, Bellone S, Black J, Schwab CL, Lopez S, Cocco E, et al. Solitomab, an EpCAM\/CD3 bispecific antibody construct (BiTE\u00ae), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. J Exp Clin Cancer Res. 2015;34:123.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1037_CR75","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13048-018-0460-6","volume":"11","author":"A Swiatly","year":"2018","unstructured":"Swiatly A, Plewa S, Matysiak J, Kokot ZJ. Mass spectrometry-based proteomics techniques and their application in ovarian cancer research. J Ovarian Res. 2018;11(1):88.","journal-title":"J Ovarian Res"},{"issue":"2","key":"1037_CR76","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/proteomes10020016","volume":"10","author":"A Ghose","year":"2022","unstructured":"Ghose A, Gullapalli SVN, Chohan N, Bolina A, Moschetta M, Rassy E, et al. Applications of proteomics in ovarian Cancer: Dawn of a new era. Proteomes. 2022;10(2):16.","journal-title":"Proteomes."},{"issue":"1","key":"1037_CR77","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cell.2018.08.065","volume":"175","author":"F Coscia","year":"2018","unstructured":"Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, et al. Multi-level proteomics identifies CT45 as a Chemosensitivity mediator and immunotherapy target in ovarian Cancer. Cell. 2018;175(1):159\u201370.e16.","journal-title":"Cell."},{"issue":"2","key":"1037_CR78","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/15548627.2014.998931","volume":"11","author":"SF Zhang","year":"2015","unstructured":"Zhang SF, Wang XY, Fu ZQ, Peng QH, Zhang JY, Ye F, et al. TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer. Autophagy. 2015;11(2):225\u201338.","journal-title":"Autophagy."}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-022-01037-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-022-01037-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-022-01037-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T15:03:39Z","timestamp":1663340619000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-022-01037-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1037"],"URL":"https:\/\/doi.org\/10.1186\/s13048-022-01037-6","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"assertion":[{"value":"20 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}